Lilly's Jaypirca gets FDA approval for first-line CLL/SLL without 17p deletion

FDA approved Jaypirca for previously untreated CLL/SLL without 17p deletion. In the BRUIN CLL-313 trial, pirtobrutinib showed a 94% ORR and significantly improved PFS versus bendamustine plus rituximab (HR=0.20; median PFS not reached vs 33.5 months). Jaypirca is the first non-covalent BTK inhibitor approved in the first-line setting.